SOURCE: Tulip BioMed

May 23, 2006 08:28 ET

Tulip BioMed Ships Its Disposable Surgical Instruments

New Disposable Devices Designed to Increase Safety for Patients

SAN DIEGO, CA -- (MARKET WIRE) -- May 23, 2006 -- Tulip BioMed™, Inc., formerly known as Cell Bio-Systems, Inc. (PINKSHEETS: CBSI), a developer of medical devices and patented technologies for the living tissue markets, including plastic, cosmetic, and orthopedic surgeries, today announced it has begun shipping its new disposable surgical instruments for the removal of soft tissue and fluid for the plastic surgery market. The company received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cannula devices in early May.

Tulip BioMed has begun to ship two new types of disposable surgical cannulas, in multiple tip configurations and sizes, for aesthetic body and facial contouring. In addition, it is fulfilling orders for long-awaited sample kits that have been requested by plastic and cosmetic surgeons internationally; these contain not only the cannulas, but also disposable luer-to-luer transfer devices and evaluation forms for feedback. Doctors who would like to become part of the evaluative feedback program can contact Jorge Medina, 800-978-8547 at Tulip to see if they qualify.

"Physicians who have seen our prototype materials at tradeshows throughout the U.S. and South America are excited about the disposable instruments," said Marc Pilkington, CEO of Tulip BioMed. "We hope to solve problems of air leakage, cross-contamination and tissue damage with stable disposable instruments that have a lubricious coating designed to slip easily through the tissue, increasing safety for both patient and doctor, and delivering better surgical performance as well."

The instruments developed by Tulip BioMed are designed to solve contamination issues by eliminating reuse of liposuction, fat transfer and stem cell instruments, and, because of the lubricious coating, are expected to increase the ease of manipulation for re-injection procedures. Tulip BioMed's disposable cannulas connect to any syringe via a patented SuperLuerLok™ design that holds it steady. Tulip BioMed also has a patent pending on the process used to add the lubricious coating to the instruments. The products are marketed under the Tulip Disposable brand name.

Tulip BioMed products are manufactured to meet strict US FDA standards. These disposable instruments are designed to vastly reduce the risk of infection, yield more predictable results, and also offer a cost-effective resource for doctors because the one-time-use instruments can be billed as a component of a procedure. More info is available at

About Tulip BioMed, Inc.

Tulip BioMed, Inc., formerly known as Cell Bio-Systems, Inc. (PINKSHEETS: CBSI), is a Nevada corporation with operations based in San Diego, California. Founded in 2004, Tulip BioMed is a medical device, biotechnology company that manufactures and distributes patented technologies for the plastic and cosmetic surgery, biopsy, orthopedic surgery, stem cell therapy and other living tissue markets. Tulip BioMed is the exclusive licensee of patented syringe connection devices that use the worldwide recognized Tulip brand name. Tulip BioMed manufactures, markets, and distributes medical devices, adapted with these and other patented technologies, to physicians, clinics, military, health organizations, hospitals and other distribution outlets. On the Web:

Safe Harbor: This press release contains certain forward-looking information about Tulip BioMed ("Tulip") which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tulip BioMed, Inc. that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy. We are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission. We trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Tulip BioMed, Inc. does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information

  • Contact:
    Beth Walsh
    Clearpoint Agency, Inc.
    Email Contact